Cell Nature Science 2026;1(1):e00003
https://doi.org/10.61474/cns.00003

From Sex-Specific Medicine to Xenocortication: A Triangulated Research Brief on Current Frontiers in Medicine and Biology

— A Research Brief on Frontier Progress, October 2026

Dan-Dan Wang[1]

1 Parkway Xintiandi Medical Center, Shanghai, 200001, People's Republic of China

**Correspondence to: Wang DD, Parkway Xintiandi Medical Center, 138 Middle Huaihai Rd., Shanghai, 200001, People's Republic of China, E-mail: drwangdandan@outlook.com*

Citation of this article: Wang DD. From Sex-Specific Medicine to Xenocortication: A Triangulated Research Brief on Current Frontiers in Medicine and Biology—A Research Brief on Frontier Progress, October 2026. Cell Nat Sci 2026;1(1):e00003. doi: 10.61474/cns.2026.00003.

Published online: October 15, 2026

Abstract

This research brief triangulates two current issues of leading international journals against the review literature that anticipated them. It first summarizes seven articles—three original studies and four reviews—from a themed issue of a leading international science journal (Vol. 394, No. 6819) devoted to sex-specific and women′s health, spanning metabolism, cancer, osteoarthritis, maternal physiology, sex chromosomes, menopause and chronic pain. It then reviews seven original studies from a companion international research issue (Vol. 658, No. 8135) covering human–mouse xenocortication, sleep-promoting cortical circuits, mTORC1-linked longevity, tumour-draining lymph-node checkpoints, extrachromosomal DNA maintenance and the monkeypox virus replisome. Finally, it reads these fourteen front-line studies against eleven syntheses published in 2023—on proteostasis in retinal ageing, excitotoxicity and neural repair, checkpoint cytology, single-cell annotation, ocular imaging, comparative pharmacology and vaccine hesitancy—showing how each anticipated a theme now at the frontier.

Keywords: sex-specific medicine; women′s health; xenocortication; sleep circuits; mTORC1 and lifespan; extrachromosomal DNA; immune checkpoint; vaccine hesitancy

Editorial

Biomedical publishing in 2026 rewards synthesis as much as discovery. The present communication deliberately reads two current issues of leading international journals against one another and against the review literature that came before them: a themed issue of a leading international science journal (Vol. 394, No. 6819) that places sex as a biological variable at centre stage, and a companion issue of an international research journal (Vol. 658, No. 8135) that advances the molecular machinery of the brain, longevity, cancer and virology. The rationale is triangulation—front-line discoveries mean more when they are mapped onto the syntheses that anticipated them, and the discipline of review writing earns its keep when its earlier pages are shown to have asked the questions the field is now answering. The

fourteen frontier studies below are summarized with commentary, followed by a thematic reading of eleven syntheses published in 2023 whose subjects converge with the new findings.

1. Sex as a Biological Variable: A Themed Issue of a Leading International Science Journal

1.1 SLC25A34 integrates circadian, dietary and thermal control of adipocyte lipid cycling

Adipocyte lipid metabolism is coordinated by circadian rhythms, diet and environmental temperature, but the molecular integrator of these cues was unknown. Karavaeva and colleagues show that the orphan mitochondrial carrier SLC25A34 is the convergence point: the adipocyte clock suppresses Slc25a34 through REV-ERB repressors during the sleep phase, whereas feeding, lipid-rich diets and cold exposure relieve this repression via PPAR-mediated transcriptional activation. SLC25A34 is proposed to import oxaloacetate into mitochondria, jointly supporting the tricarboxylic acid cycle and cytosolic acetyl-CoA production, which in turn fuels lipid synthesis and induces genes enhancing mitochondrial oxidation.

Commentary: By naming a single transducer for clock, diet and temperature, this study converts three classic environmental inputs into one druggable mitochondrial node, with implications for obesity, metabolic disease and circadian disruption. Translating SLC25A34 biology from mouse adipocytes to human therapy will require potent and selective chemical probes, which do not yet exist.[1]

1.2 p53 loss generates a Wnt signalling gradient that drives epithelial clonal expansion

TP53 mutations are among the most common lesions in epithelial cancers, yet how p53 loss unleashes clonal expansion has remained unclear. Working in mouse epidermis, Gan and colleagues show that p53 normally limits progenitor self-renewal through a network in which Sfrp1, Lrp1 and Usp22 are direct p53 targets; their suppression after p53 loss generates a radial gradient of Wnt activity across mutant clones. Genetic experiments indicate that it is the gradient—rather than uniform elevation—of Wnt activity that sustains clonal expansion, identifying spatial organization of signalling as a determinant of mutant clone behaviour.

Commentary: This work reframes tumour-suppressor biology in spatial terms: mutant clones do not merely outgrow neighbours, they organize a signalling geography that colonizes tissue. The gradient concept offers a new lens for understanding field cancerization

and suggests that targeting Wnt-spreading mechanisms could restrain premalignant expansion before invasive disease.[2]

1.3 Hypertension accelerates osteoarthritis through AVP–AVPR1A neuroendocrine signalling

Osteoarthritis (OA) progression is accelerated by systemic metabolic stress, but mechanistic links between common comorbidities and joint degeneration have been lacking. Kim and colleagues establish that hypertension fuels OA pathogenesis in joints predisposed by mechanical injury or ageing: OA-primed chondrocytes upregulate arginine vasopressin receptor 1A (AVPR1A), rendering them responsive to circulating AVP. AVP–AVPR1A signalling amplifies catabolic and suppresses anabolic programmes through the transcriptional mediator NR4A3, and genetic deletion or pharmacological inhibition of AVPR1A protects against hypertension-driven OA acceleration.

Commentary: This is a rare demonstration of a neuroendocrine axis coupling a vascular comorbidity to cartilage breakdown, immediately testable because AVPR1A antagonists already exist. The findings argue for cardiovascular–musculoskeletal comanagement in OA and position hypertension control as disease-modifying therapy.[3]

1.4 Four themed reviews: maternal immunity, sex chromosomes, menopause and chronic pain

The same issue carries four reviews that together stake out a sex-aware medicine. Corral and Belkaid argue that pregnancy reprograms maternal immunity so that immune cells actively instruct physiological adaptation across maternal organs—beyond the classical frame of fetal tolerance—shaping maternal health long after reproduction. Dubal and colleagues review cell-autonomous effects of the X and Y chromosomes on ageing and disease, including escape from X-inactivation, parent-of-X-origin effects, X-skew and Y-chromosome loss, urging their integration into precision medicine and trial design. Gravelsins and colleagues reframe menopause—which spans roughly 40 percent of female life and up to 72 symptoms—as an opportunity for healthy aging, emphasizing that the more than 200 hormone-therapy formulations differ materially in risk–benefit and demand precision selection. Venkataraman and colleagues synthesize sex-specific mechanisms of chronic pain, from hormone–immune–neural cross-talk to gut microbiome and endogenous analgesic circuits, explaining rather than merely describing the female predominance of pain disorders.

Commentary: Read together, the four reviews make a policy-level argument: sex is not a covariate to control but a design variable to exploit. They supply mechanistic depth—immune, chromosomal, endocrine and neural—for the trials that regulators and funders increasingly expect to be sex-aware.[4,5,6,7]

2. From Human Neural Circuits to Viral Replisomes: Highlights of a Companion International Research Issue (Vol. 658, No. 8135)

2.1 Developmental xenocortication using human-derived organoids in mice

Human brain tissue is largely inaccessible, limiting developmental and disease studies. Kaganovsky and colleagues establish xenocortical mice by genetically depleting glutamatergic neurons from the mouse neocortex and hippocampus (apallial mice) and neonatally engrafting the cavity with human cortical organoids. The grafts occupy most of the cortical volume, generate diverse human cell types including layer-5 extratelencephalic projection neurons, integrate with the host nervous system and display organized, development-like activity by in vivo calcium imaging and electrophysiology; behaviour is broadly preserved with selective limb-coordination differences, and injury models of developing human cortical cells yield behavioural readouts.

Commentary: Xenocortication substantially raises the integration ceiling of human organoids, moving them from local grafts to functionally wired participants in host circuits. It promises circuit- and behaviour-level drug testing on human neurons in vivo, while ethically and technically demanding rigorous host-welfare and identity controls.[8]

2.2 Neocortical long-range inhibition promotes cortical synchrony and sleep

Sleep is orchestrated by subcortical centres, yet cortical circuit contributions are poorly defined. Ratliff and colleagues identify a sparse, genetically distinct class of somatostatin-and-chondrolectin (Sst+Chodl+) GABAergic neurons that are selectively active during low-arousal states, silent during high arousal, and—unlike most inhibitory neurons—project long-range axons to multiple neocortical regions simultaneously. Selective activation of Sst-Chodl cells is sufficient to drive multi-region cortical synchronization characteristic of sleep and to induce sleep behaviour.

Commentary: This discovery elevates the cortex from passive follower to active sleep promoter, adding a long-range inhibitory hub to the canonical arousal circuitry. It also offers a precise, cell-type-specific handle for manipulating sleep architecture—relevant to insomnia, anaesthesia and neuropsychiatric disease.[9]

2.3 Lsp2 links mTORC1 to TOP mRNA translation and lifespan in Drosophila

mTORC1 couples nutrient sensing to growth, yet how its translational output is physiologically tuned remains unclear. Wang and colleagues show that Lsp2—previously known as a storage protein—is an adipose effector and feedback activator of mTORC1: essential amino acids induce Lsp2 through mTORC1, and Lsp2 in turn amplifies translation of 5-prime-terminal oligopyrimidine (TOP) mRNAs, which encode ribosomal proteins, in a

4E-BP-dependent manner. Genetic ablation of Lsp2 selectively dampens global TOP-mRNA translation and robustly extends lifespan without impairing reproduction, through a mechanism distinct from rapamycin.

Commentary: This study uncovers a nutrient-induced rheostat that sets the cell′s translational burden, revealing a non-rapamycin entry point into mTORC1 output that uncouples longevity from reproduction. Whether mammals harbour an analogous TOP-translation governor is now an urgent question for ageing research.[10]

2.4 Lsp2 carries early-life diet into adult translation and lifespan

Complementing the above, Kosakamoto and colleagues show that larval protein restriction (ePR) in Drosophila promotes adult lifespan by durably downregulating Lsp2: larval dietary amino acids are traced into adult ribosomal proteins, and silencing Lsp2 phenocopies ePR, attenuating ribosomal-protein abundance and translation in early adulthood. Restricting amino acids especially enriched in storage proteins—phenylalanine and tyrosine—is sufficient to lower early-life Lsp2 and extend life.

Commentary: Together the two Lsp2 papers define nutritional memory—a molecular carrier that records juvenile diet and reprograms adult translation. The work supplies a concrete, amino-acid-level mechanism for developmental nutritional programming with direct dietary levers.[11]

2.5 PLA2G2D in tumour-draining lymph nodes regulates anti-tumour immunity

T-cell priming in tumour-draining lymph nodes (TDLNs) governs systemic anti-tumour immunity, but suppression within TDLNs is poorly characterized. Using imaging mass cytometry of melanoma TDLNs, van Krimpen and colleagues identify a paracortical spatial neighbourhood linked to distant metastasis, in which activated CD8+ T cells engage PLA2G2D-high myeloid cells. PLA2G2D+ myeloid cells are more abundant in TDLNs than in tumours; genetic or antibody-mediated PLA2G2D inhibition markedly reduces tumour growth, expands tumour-specific T cells and acts non-redundantly with PD-1 blockade, with additive or synergistic benefit in humanized mice.

Commentary: By relocating checkpoint biology from the tumour bed to the draining node, this study identifies a spatially defined, targetable brake on priming itself. Combination of PLA2G2D blockade with PD-1 therapy is a compelling, near-clinical hypothesis for checkpoint-refractory disease.[12]

2.6 MMEJ repair of breaks at TA repeats maintains extrachromosomal DNA and cancer fitness

Extrachromosomal DNA (ecDNA) carrying oncogene amplifications drives aggressive, resistant tumours, but the pathways maintaining it were unclear. Billing and colleagues show that microhomology-mediated end joining (MMEJ)—but not classical NHEJ or homologous recombination—selectively maintains ecDNA: TA-rich loci are breakage hotspots, the translocase FANCM suppresses breaks, and escaped breaks are cleaved by ERCC1-ERCC4 and channelled into MMEJ. Inhibiting MMEJ, particularly polymerase θ (Polθ), depletes ecDNA, sequesters it in micronuclei and compromises fitness of ecDNA-driven cancers, mirroring TA-enriched rearrangements in human tumours.

Commentary: This work turns an intrinsic fragility of circular DNA into a therapeutic strategy and provides a mechanistic rationale for Polθ inhibitors against ecDNA-driven cancers—a growing fraction of aggressive disease. Biomarkers of TA-repeat instability may help select responders.[13]

2.7 Structure and operating principles of a monkeypox virus replisome

Monkeypox virus (MPXV) has caused two recent WHO-declared public health emergencies, yet how its replication machinery assembles was unknown. Yu and colleagues used cryo-electron microscopy to determine structures of DNA-bound MPXV replisomes comprising the polymerase holoenzyme (F8 with the A22-E4 processivity factor) and the E5 helicase hexamer. Assembly drives large conformational changes in E5, coupling two primase domains to the polymerase F8 thumb and A22 subunit; biochemical and single-molecule assays show this reconfiguration activates the otherwise autoinhibited helicase and enhances primase activity.

Commentary: The replisome architecture reveals where coordinated helicase–polymerase activity can be attacked, offering structure-guided starting points for antipoxviral drug design against a continuing public-health threat and a broader class of large DNA viruses.[14]

3. Echoes from 2023: Syntheses That Anticipated the Frontiers

Read against the review literature of 2023, the fourteen studies above lose their novelty in the best possible way: several of these frontiers were anticipated, sometimes precisely, by syntheses published that year. We highlight eleven such syntheses below, organized by theme rather than by provenance, and indicate in each case where the anticipation now meets the frontier.

3.1 Synthesis as scholarship

An inaugural editorial published in 2023 argued that high-impact research too often remains confined to specialized circles, and that the disciplined reinterpretation of complex findings for a wider scientific audience is itself scholarly work. The present brief is written in exactly that spirit, and the ten syntheses that follow show what such reinterpretation can accomplish.[15]

3.2 Proteostasis and translational burden in retinal ageing

A 2023 review of the ubiquitin–proteasome system and autophagy in age-related macular degeneration mapped how the two principal clearance pathways and their interplay shape drusen pathogenesis, evaluated existing treatments and charted proteostasis-targeting drug development. The Lsp2 studies of 2026 now supply the translational-burden counterpart: a nutrient-induced rheostat that sets how much TOP mRNA a cell translates, directly linking protein-economy control to lifespan. Protein quality control and translational budgeting, treated separately in 2023 and 2026, are converging on ageing as a druggable programme.[16,10,11]

3.3 Excitotoxicity and the retinal ganglion cell

Also in 2023, the first review of D-serine—the NMDA-receptor co-agonist—in retinal physiology traced how serine racemase and D-amino acid oxidase set its levels, how it potentiates NMDAR currents in retinal ganglion cells, and how modulating it attenuates ganglion-cell death in diabetic retinopathy and glaucoma models. The neuroscience of 2026 has meanwhile acquired circuit-level handles on neural protection and state control—from xenocorticated human circuits to sleep-promoting long-range inhibitory neurons—into which glial and neuromodulatory control of excitotoxicity now slots naturally.[17,8,9]

3.4 Engineering neural repair

A 2023 survey of bioscaffolds supporting Schwann cells emphasized the PI3K/AKT/mTOR pathway and the control of autophagy and inflammation as molecular levers for nerve regeneration. Three years on, mTOR signalling has emerged as a longevity governor through the same pathway′s translational arm, and human neural tissue can be grown inside mouse hosts—two advances that materially expand the scaffold designer′s toolkit.[18,10,8]

3.5 The ocular burden of myopia

A 2023 review consolidated the epidemiological and pathological links between myopia and early-onset cataract, the chronic lens changes wrought by lifelong myopic progression,

and the surgical challenges of highly myopic eyes—an agenda of early detection and targeted management for working-age vision that remains fully current.[19]

3.6 Comparative pharmacology across species

In 2023, a network-pharmacology study of the excipient trehalose quantified significant species differences in target profiles and trehalase affinity across human, mouse and rat, identifying cyclin-dependent kinase 1 as a high-affinity target and cautioning against naive rodent translation. That caution has since become a governing premise: the sex-chromosome and sex-specific-pain reviews of 2026 argue that biology varies systematically between populations, and that pharmacology must be designed for the difference rather than averaged over it.[20,5,7]

3.7 Checkpoint cytology in melanoma

A 2023 cytomorphological study of melanoma found CTLA-4 and PD-L1 absent from malignant cells and concentrated instead in tumour-associated macrophages and dendritic cells, with CTLA-4 expression extending beyond T lymphocytes—evidence that checkpoint molecules operate through a wider cellular network than the classical scheme. The 2026 identification of PLA2G2D+ myeloid neighbourhoods gating T-cell priming in tumour-draining lymph nodes vindicates and extends that insight: the decisive checkpoint action may occur in the node, not the tumour bed.[21,12]

3.8 Democratizing single-cell annotation

In 2023, an openly shared Microsoft-Excel template enabled bench scientists to identify mouse central nervous system myeloid-cell subtypes from single-cell RNA-sequencing data with 93.98 percent consistency against the literature. The spatial single-cell and imaging-mass-cytometry methods that now define lymph-node immune geography are, at their core, the same operation—assigning identity to cells in context—executed with heavier machinery.[22,12]

3.9 Multimodal imaging of chorioretinopathy

A 2023 review integrated optical coherence tomography, fluorescein and indocyanine-green angiography, en face OCT, OCT angiography, autofluorescence and multispectral imaging for central serous chorioretinopathy, distinguishing acute from chronic disease and non-invasively detecting neovascular components. As imaging biomarkers increasingly anchor trials in ophthalmology and beyond, such integration remains the template for phenotype-to-mechanism translation.[23]

3.10 Immune-checkpoint inhibitors in triple-negative breast cancer

A 2023 review synthesized PD-1/PD-L1 blockade in triple-negative breast cancer, appraising predictive markers—PD-L1, tumour mutational burden, stromal tumour-infiltrating lymphocytes and CD8-positive T cells—and combinations with chemotherapy, PARP inhibitors, antibody–drug conjugates and anti-angiogenic agents. The 2026 frontier adds two mechanistic bookends: the p53-loss Wnt gradient that organizes premalignant epithelial expansion upstream of immunotherapy, and the PLA2G2D checkpoint that gates priming downstream of antigen availability—together bracketing where immunotherapy can and cannot act.[24,2,12]

3.11 Vaccine hesitancy

Finally, a 2023 analysis dissected vaccine hesitancy across socio-cultural, economic and political dimensions, cognitive biases and misinformation, distilling a framework for targeted communication. It is a necessary reminder that even the most elegant replisome structure delivers value only if it reaches the populations that need it—the social substrate of every virological advance.[25,14]

Concluding Remarks

Triangulated, the literature of 2023 and 2026 tells one story. Sex-aware design is moving from advocacy to mechanism; the brain is yielding circuit-level and even cross-species handles on development, sleep and disease; longevity research has acquired amino-acid-specific, translation-centred levers; cancer biology is being reorganized around spatial gradients, lymph-node checkpoints and circular-DNA maintenance; and structural virology continues to convert emergencies into drug targets. The syntheses of 2023 anticipated each of these arcs, and they remain durable entry points for readers entering these fields. The pace at which such findings travel from page to practice will define the coming decade of medicine.

Copyright and Republishing Notice

This communication is an independent scholarly summary and commentary written by the author on the basis of publicly available publication listings and abstracts; the text is original and does not constitute a translation or reproduction of the original articles. Copyright in the reviewed papers remains with their authors and publishers; the author names, titles, volume, page and DOI information cited herein are provided solely as academic signposts. Copyright in the original abstracts, figures and journal cover images belongs to the publishers or authors and must not be reproduced without permission. This article does not represent the position of any publisher, nor has it been authorized or endorsed by one.

Properly attributed citation and link-sharing are welcome; permission from the author is required for full-text republication.

References

[1] Karavaeva I, Basse AL, Trammell SAJ, et al. Mitochondrial carrier SLC25A34 links clock, diet, and temperature control of adipocyte lipid cycling. Science, 2026, 394(6819): eadz4797. DOI: 10.1126/science.adz4797.

[2] Gan Q, Li W, Lex RK, et al. Loss of the tumor suppressor p53 generates a signaling gradient that drives epithelial clonal expansion. Science, 2026, 394(6819): eaed3065. DOI: 10.1126/science.aed3065.

[3] Kim SJ, Kim HE, Chung KH, et al. Hypertension fuels osteoarthritis through neuroendocrine signaling. Science, 2026, 394(6819): eaed8207. DOI: 10.1126/science.aed8207.

[4] Corral D, Belkaid Y. Shaping maternal physiology: Immune control of reproductive adaptation. Science, 2026, 394(6819): 46-52. DOI: 10.1126/science.aeh1405.

[5] Dubal DB, Ambrosio F, Stout MB, et al. X and Y chromosomes as determinants of aging and disease. Science, 2026, 394(6819): 53-59. DOI: 10.1126/science.aeh0145.

[6] Gravelsins LL, Perović M, Alexander MW, et al. Reframing menopause and menopause hormone therapy as opportunities for healthy aging. Science, 2026, 394(6819): 60-68. DOI: 10.1126/science.aeg5004.

[7] Venkataraman A, Midavaine É, Ingraham HA. Sex-specific mechanisms of chronic pain. Science, 2026, 394(6819): 69-74. DOI: 10.1126/science.aeh4468.

[8] Kaganovsky K, Kelley KW, Gschwind T, et al. Developmental xenocortication using human-derived organoids in mice. Nature, 2026, 658(8135): 430-441. DOI: 10.1038/s41586-026-11032-2.

[9] Ratliff JM, Terral G, Vazquez A, et al. Neocortical long-range inhibition promotes cortical synchrony and sleep. Nature, 2026, 658(8135): 442-453. DOI: 10.1038/s41586-026-10876-y.

[10] Wang J, Cai Z, Gu J, et al. Lsp2 links mTORC1 to TOP mRNA translation and lifespan in Drosophila. Nature, 2026, 658(8135): 465-473. DOI: 10.1038/s41586-026-11029-x.

[11] Kosakamoto H, Okada R, Barker CS, et al. Lsp2 links early-life diet to adult translation and lifespan in Drosophila. Nature, 2026, 658(8135): 474-484. DOI: 10.1038/s41586-026-11031-3.

[12] van Krimpen A, Huang J, Eterman M, et al. PLA2G2D in tumour-draining lymph nodes regulates anti-tumour immunity. Nature, 2026, 658(8135): 485-495. DOI: 10.1038/s41586-026-10954-1.

[13] Billing D, Selvaraj M, Kelley ME, et al. MMEJ repair of breaks at TA repeats maintains ecDNA and cancer fitness. Nature, 2026, 658(8135): 525-535. DOI: 10.1038/s41586-026-11048-8.

[14] Yu Z, Sathyanarayana P, Tan JMJ, et al. Structure and operating principles of a monkeypox virus replisome. Nature, 2026, 658(8135): 547-555. DOI: 10.1038/s41586-026-10937-2.

[15] Zhao MW. The Launch of Nature Cell and Science. Nat Cell Sci, 2023, 1(1): 1. DOI: 10.61474/ncs.2023.00010.

[16] Xu N, Li J, Chen X, et al. Association Between Autophagy and Ubiquitin-proteasome System in Age-related Macular Degeneration. Nat Cell Sci, 2023, 1(1): 2-8. DOI: 10.61474/ncs.2023.00011.

[17] Zhou P, Wu S. The Physiological and Pathological Roles of D-serine in the Retina. Nat Cell Sci, 2023, 1(1): 9-15. DOI: 10.61474/ncs.2023.00003.

[18] Suga N, Taniguchi K, Sawamura H, et al. Advantageous Tactics for the Development of Bioscaffolds to Support Schwann Cells Aimed at Superior Neural Regeneration. Nat Cell Sci, 2023, 1(1): 16-23. DOI: 10.61474/ncs.2023.00002.

[19] Wei L, Zhang KK, Lu Y, et al. Myopia and Cataract. Nat Cell Sci, 2023, 1(1): 24-31. DOI: 10.61474/ncs.2023.00002a.

[20] Friend J, Kumar AHS. A Network Pharmacology Approach to Assess the Comparative Pharmacodynamics of Pharmaceutical Excipient Trehalose in Human, Mouse, and Rat. Nat Cell Sci, 2023, 1(2): 33. DOI: 10.61474/ncs.2023.00012.

[21] Tiemann M, Samoilova V, Atiakshin D, et al. The Cytomorphology of Melanoma with a Special Emphasis on the Immune Checkpoint Proteins CTLA-4, PD-1, and PD-L1. Nat Cell Sci, 2023, 1(2): 44. DOI: 10.61474/ncs.2023.00013.

[22] Lyu XY, Li JL, Ding SQ, et al. A Microsoft-Excel Template for Identifying Mouse Myeloid Cell Types in the Central Nervous System Based on Single-cell RNA Sequencing Data. Nat Cell Sci, 2023, 1(2): 53.

[23] Jin EZ. Multimodal Fundus Imaging for Central Serous Chorioretinopathy. Nat Cell Sci, 2023, 1(2): 66-72. DOI: 10.61474/ncs.2023.00033.

[24] Sui XY, Fan L. Immune Checkpoint Inhibitors in Triple-negative Breast Cancer. Nat Cell Sci, 2023, 1(2): 73-79. DOI: 10.61474/ncs.2023.00035.

[25] Qadrie Z, Dar MA, Maqbool M, et al. Vaccine Hesitancy Unmasked: Unraveling Its Enigmatic Threads. Nat Cell Sci, 2023, 1(2): 80-87. DOI: 10.61474/ncs.2023.00009.

(This article was prepared on the basis of publicly available publication listings and abstracts, for academic exchange only.)